|
Disease |
Occurrence (%) |
Graft loss (%) |
|
aHUSa |
15-100 |
~50 |
|
Amyloidosis |
20-40 |
N/A |
|
ANCA-associated vasculitis |
~17 |
<10 |
|
Anti-GBM disease |
20-30 |
<10 |
|
C3 glomerulopathya |
60-80 |
35-50 |
|
Fibrillary glomerulopathy |
~50 |
N/A |
|
FSGS |
20-50 |
10-40 |
|
IgA nephropathy |
30-60 |
15-30 |
|
IgA vasculitis (previously Henoch-Schönlein purpura) |
~50 |
10-20 |
|
Light chain deposition disease |
~50 |
N/A |
|
Lupus nephropathy |
1 |
Rarely |
|
Membranous nephropathy |
20-30 |
~30 |
|
Mixed idiopathic cryoglobulinemia |
~70 |
N/A |
|
Systemic scleroderma |
~20 |
N/A |
|
Waldenström macroglobulinemia |
10-25 |
N/A |
|
a Depending on the mutation of genes encoding proteins regulating the activity of the alternative complement pathway and type of prophylaxis used. |
||
|
aHUS, atypical hemolytic-uremic syndrome; ANCA, antineutrophil cytoplasmic antibody; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; N/A, not available. |
||